93 related articles for article (PubMed ID: 17943579)
21. Utility and efficacy of fluticasone propionate and salmeterol inhaled from a single inhaler for persistent asthma.
Mathison DA; Koziol JA
J Asthma; 2005 Dec; 42(10):829-31. PubMed ID: 16393719
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
[TBL] [Abstract][Full Text] [Related]
23. Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma.
Delea TE; Hagiwara M; Stanford RH; Stempel DA
Clin Ther; 2008 Mar; 30(3):560-71. PubMed ID: 18405796
[TBL] [Abstract][Full Text] [Related]
24. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.
Singh D; Brooks J; Hagan G; Cahn A; O'Connor BJ
Thorax; 2008 Jul; 63(7):592-8. PubMed ID: 18245142
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of nebulized fluticasone propionate in adult patients admitted to the emergency department due to bronchial asthma attack.
Starobin D; Bolotinsky L; Or J; Fink G; Shtoeger Z
Isr Med Assoc J; 2008; 10(8-9):568-71. PubMed ID: 18847151
[TBL] [Abstract][Full Text] [Related]
26. [Budesonide/formoterol maintenance and reliever therapy. A new treatment approach for adult patients with asthma].
Korn S; Vogelmeier C; Buhl R
Med Klin (Munich); 2008 May; 103(5):299-310. PubMed ID: 18484216
[TBL] [Abstract][Full Text] [Related]
27. [Study of personal best value of peak expiratory flow in patients with asthma--comparison of the highest value of daily PEF under good control and the highest value of daily PEF obtained after using repeated inhaled beta2-agonist during high-dose inhaled steroid treatment].
Watanabe N; Makino S; Kihara N; Fukuda T
Arerugi; 2008 Dec; 57(12):1284-92. PubMed ID: 19169083
[TBL] [Abstract][Full Text] [Related]
28. Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent allergic asthma.
Humbert M; Berger W; Rapatz G; Turk F
Allergy; 2008 May; 63(5):592-6. PubMed ID: 18355388
[TBL] [Abstract][Full Text] [Related]
29. Retrospective claims study of fluticasone propionate/salmeterol fixed-dose combination use as initial asthma controller therapy in children despite guideline recommendations.
Friedman HS; Eid NS; Crespi S; Wilcox TK; Reardon G
Clin Ther; 2009 May; 31(5):1056-63. PubMed ID: 19539106
[TBL] [Abstract][Full Text] [Related]
30. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations.
Slavin RG; Ferioli C; Tannenbaum SJ; Martin C; Blogg M; Lowe PJ
J Allergy Clin Immunol; 2009 Jan; 123(1):107-113.e3. PubMed ID: 19130931
[TBL] [Abstract][Full Text] [Related]
31. Comparison of mometasone furoate dry powder inhaler and fluticasone propionate dry powder inhaler in patients with moderate to severe persistent asthma requiring high-dose inhaled corticosteroid therapy: findings from a noninferiority trial.
Harnest U; Price D; Howes T; Sussman G
J Asthma; 2008 Apr; 45(3):215-20. PubMed ID: 18415829
[TBL] [Abstract][Full Text] [Related]
32. Benefits of low-dose inhaled fluticasone on airway response and inflammation in mild asthma.
Boulet LP; Turcotte H; Prince P; Lemière C; Olivenstein R; Laprise C; Larivée P; Bégin P; Laviolette M
Respir Med; 2009 Oct; 103(10):1554-63. PubMed ID: 19692221
[TBL] [Abstract][Full Text] [Related]
33. [Influence of education level on self-evaluation and control of patients with bronchial asthma].
Zhao HJ; Cai SX; Tong WC; Li WJ; Fu L
Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):715-7. PubMed ID: 18504187
[TBL] [Abstract][Full Text] [Related]
34. Time required to achieve asthma control in not previously inhaled corticosteroid treated adult patients.
Ramos Costa Mdo R; de Oliveira MA; Caetano LB; Santoro IL; Godoy Fernandes AL
J Asthma; 2008 Sep; 45(7):579-82. PubMed ID: 18773330
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.
Earnshaw SR; Wilson MR; Dalal AA; Chambers MG; Jhingran P; Stanford R; Mapel DW
Respir Med; 2009 Jan; 103(1):12-21. PubMed ID: 19010652
[TBL] [Abstract][Full Text] [Related]
36. Rapid corticosteroid effect on beta(2)-adrenergic airway and airway vascular reactivity in patients with mild asthma.
Mendes ES; Horvath G; Campos M; Wanner A
J Allergy Clin Immunol; 2008 Mar; 121(3):700-4. PubMed ID: 18086493
[TBL] [Abstract][Full Text] [Related]
37. Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire.
Juniper EF; Bousquet J; Abetz L; Bateman ED;
Respir Med; 2006 Apr; 100(4):616-21. PubMed ID: 16226443
[TBL] [Abstract][Full Text] [Related]
38. Asthma control: do patients' and physicians' opinions fit in with patients' asthma control status?
Prieto L; Badiola C; Villa JR; Plaza V; Molina J; Cimas E
J Asthma; 2007; 44(6):461-7. PubMed ID: 17654133
[TBL] [Abstract][Full Text] [Related]
39. Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study.
Donohue JF; Hanania NA; Ciubotaru RL; Noe L; Pasta DJ; Schaefer K; Claus R; Andrews WT; Roach J
Clin Ther; 2008; 30 Spec No():989-1002. PubMed ID: 18640474
[TBL] [Abstract][Full Text] [Related]
40. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
Ferguson GT; Anzueto A; Fei R; Emmett A; Knobil K; Kalberg C
Respir Med; 2008 Aug; 102(8):1099-108. PubMed ID: 18614347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
